Compounders Research Compare

Oncolytics Biotech Inc.(ONCY)

Biotechnology · San Diego, CA

$0.59-0.00 (-0.40%)

Delayed quote: Oct 6, 2026, 12:13 PM EDT

About Oncolytics Biotech Inc.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

San Diego, CA

29 employees

www.oncolyticsbiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jared Kelly

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T16:18:11.360Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:18:11.360Z.

Quote observation: 2026-10-06T16:13:31.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 59,664,615
Total debt · period ending 2026-06-30: 448,000
Cash · period ending 2026-06-30: 4,115,000
TTM operating EBITDA · period ending 2026-06-30: N/A

FMP input reference: d71c6897c98d436948f76d79272a6a7ae3c560285f8867db41996dc6a6301e16

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ONCY EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

ONCY Competitors' EV/EBITDA Ratio

Oncolytics Biotech Inc.

Current

Market Cap

$59.66M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PDS Biotechnology Corporation

Market Cap

$60.39M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Adicet Bio, Inc.

Market Cap

$60.54M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Connect Biopharma Holdings Limited

Market Cap

$60.88M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MiNK Therapeutics, Inc.

Market Cap

$58.29M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Fractyl Health, Inc.

Market Cap

$58.57M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Boundless Bio, Inc.

Market Cap

$57.65M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

InterCure Ltd.

Market Cap

$63.02M

EV/EBITDA Ratio

N/A

TTM Avg

7.83x

3Y Avg

18.88x

5Y Avg

17.80x

Kalaris Therapeutics Inc

Market Cap

$61.12M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OKYO Pharma Limited

Market Cap

$56.98M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Oncolytics Biotech Inc. (ONCY)	$59.66M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$60.39M	N/A	N/A	N/A	N/A
Adicet Bio, Inc. (ACET)vs ›	$60.54M	N/A	N/A	N/A	N/A
Connect Biopharma Holdings Limited (CNTB)vs ›	$60.88M	N/A	N/A	N/A	N/A
MiNK Therapeutics, Inc. (INKT)vs ›	$58.29M	N/A	N/A	N/A	N/A
Fractyl Health, Inc. (GUTS)vs ›	$58.57M	N/A	N/A	N/A	N/A
Boundless Bio, Inc. (BOLD)vs ›	$57.65M	N/A	N/A	N/A	N/A
InterCure Ltd. (INCR)vs ›	$63.02M	N/A	7.83x	18.88x	17.80x
Kalaris Therapeutics Inc (KLRS)vs ›	$61.12M	N/A	N/A	N/A	N/A
OKYO Pharma Limited (OKYO)vs ›	$56.98M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics